作者
Sebastian A Mikolajczak, Viswanathan Lakshmanan, Matthew Fishbaugher, Nelly Camargo, Anke Harupa, Alexis Kaushansky, Alyse N Douglass, Michael Baldwin, Julie Healer, Matthew O'neill, Thuan Phuong, Alan Cowman, Stefan HI Kappe
发表日期
2014/9/1
期刊
Molecular therapy
卷号
22
期号
9
页码范围
1707-1715
出版商
Elsevier
简介
Immunization with live-attenuated Plasmodium sporozoites completely protects against malaria infection. Genetic engineering offers a versatile platform to create live-attenuated sporozoite vaccine candidates. We previously generated a genetically attenuated parasite (GAP) by deleting the P52 and P36 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52−/p36− GAP). Preclinical assessment of p52−/p36− GAP in a humanized mouse model indicated an early and severe liver stage growth defect. However, human exposure to >200 Pf p52−/p36− GAP-infected mosquito bites in a safety trial resulted in peripheral parasitemia in one of six volunteers, revealing that this GAP was incompletely attenuated. We have now created a triple gene deleted GAP by additionally removing the SAP1 gene (Pf p52−/p36−/sap1− GAP) and employed flippase (FLP)/flippase recognition target (FRT) recombination …
学术搜索中的文章
SA Mikolajczak, V Lakshmanan, M Fishbaugher… - Molecular therapy, 2014